iVis Technologies is pleased to announce that it has been undertaking the expansion works of its corporate headquarters since June 2022.
iVis Technologies is pleased to announce the closing of a framework agreement with TIM, the Politecnico di Bari and the University of Bari to perform the first remotely controlled corneal surgery
The 40th edition of the ESCRS congress, held in Milan from 16 to 20 September 2022, saw iVis playing a leading role in innovation, presenting to the arena the utmost news on the 4D Suite™ integrated platform for customized corneal surgery.
We were pleased to have you at the 13th iVis International Users’ Meeting.
The Meeting was focused on the CIPTA® Web application with three dedicated sessions:
- Session 1: Principles, Definitions, Settings, and Web Communication protocol
- Session 2: Customized ray-tracing ablation plans for phakic and pseudo-phakic eyes
- Session 3: Preliminary Outcomes and Live Surgery
iVis’ European Patent EP 1 649 843 relates to an intelligent control of the areal power density delivered by laser systems in corneal surgery.
We are pleased to announce the CE approval on iRes™2, our fastest 2.0Khz excimer laser, empowering the smallest 350um laser micro-spot to execute iVis proprietary full automated, real-time controlled, no-touch, cTen® surgical procedure, maximizing surgical performance and avoiding intra-operative risks.
We are pleased to announce the CE approval on CIPTA®2, the unique cloud-based software conceived for interactive ray-tracing customized corneal surgical planning
We are pleased to announce the achievement of the CE mark on SafeCross®+ medical device on May 7th, 2021.
SafeCross®+ is a riboflavin ophthalmic solution, patented by iVis Technologies, granting high cross-linking efficiency in poor oxygen environment.
